Literature DB >> 3554294

Psychologic treatment for the type A behavior pattern and for coronary heart disease: a meta-analysis of the literature.

E V Nunes, K A Frank, D S Kornfeld.   

Abstract

The Type A behavior pattern (TABP) is a recognized risk factor for coronary heart disease (CHD), and yet treatments aimed at its modification are not in widespread use. We reviewed the literature of controlled studies (N = 18) of the psychologic treatment of the TABP and of CHD with the statistical method of "meta-analysis." The results of each study were converted to a standardized "Effect Size" (ES). The mean ES for TABP measures was 0.61 +/- 0.20 (95% confidence interval) (p less than 0.001), indicating that after treatment subjects across all studies reduced their TABP scores by half a standard deviation. The combined significance probability (pc) across studies for reduction in 3-year combined mortality and myocardial infarction was pc less than 0.0001, corresponding to a reduction in coronary events of roughly 50% after psychologic treatment. This finding must be approached with caution because it is based on only two studies. The analysis suggested that a combination of treatment techniques is most effective in reducing TABP and CHD recurrences. The literature was critiqued, and limitations of the findings are discussed. We conclude that psychologic intervention to reduce TABP may improve clinical outcome of CHD and that this deserves further study and preliminary clinical application.

Entities:  

Mesh:

Year:  1987        PMID: 3554294     DOI: 10.1097/00006842-198703000-00006

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  10 in total

1.  Modification of the Type A behavior pattern in post-myocardial infarction patients: a route to cardiac rehabilitation.

Authors:  G Burell; A Ohman; G Ström; B Ramund; I Cullhed; C E Thoresen
Journal:  Int J Behav Med       Date:  1994

2.  Clinical Evidence: Psychosocial factors in the etiology and prognosis of coronary heart disease: systematic review of prospective cohort studies.

Authors:  H Hemingway; M Marmot
Journal:  West J Med       Date:  1999-11

Review 3.  Coronary-prone behavior. Type A behavior revisited.

Authors:  B L Lachar
Journal:  Tex Heart Inst J       Date:  1993

4.  Associations between Hunter Type A/B Personality and Cardiovascular Risk Factors from Adolescence through Young Adulthood.

Authors:  Benjamin D Pollock; Wei Chen; Emily W Harville; Lydia A Bazzano
Journal:  Int J Behav Med       Date:  2017-08

Review 5.  Psychosocial stress and cardiovascular disease: pathophysiological links.

Authors:  C Noel Bairey Merz; James Dwyer; Cheryl K Nordstrom; Kenneth G Walton; John W Salerno; Robert H Schneider
Journal:  Behav Med       Date:  2002       Impact factor: 3.104

Review 6.  Mental stress and myocardial ischemia. Correlates and potential interventions.

Authors:  C N Merz; D S Krantz; A Rozanski
Journal:  Tex Heart Inst J       Date:  1993

Review 7.  Psychosocial stress and cardiovascular disease Part 2: effectiveness of the Transcendental Meditation program in treatment and prevention.

Authors:  Kenneth G Walton; Robert H Schneider; Sanford I Nidich; John W Salerno; Cheryl K Nordstrom; C Noel Bairey Merz
Journal:  Behav Med       Date:  2002       Impact factor: 3.104

8.  Comparing multifactorial lifestyle interventions and stress management in coronary risk reduction.

Authors:  Orjan Sundin; Jan Lisspers; Claes Hofman-Bang; Ake Nygren; Lars Rydén; Arne Ohman
Journal:  Int J Behav Med       Date:  2003

Review 9.  Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease. Systematic review of prospective cohort studies.

Authors:  H Hemingway; M Marmot
Journal:  BMJ       Date:  1999-05-29

10.  Psychosocial stress and cardiovascular disease. Part 3: Clinical and policy implications of research on the transcendental meditation program.

Authors:  Kenneth G Walton; Robert H Schneider; John W Salerno; Sanford I Nidich
Journal:  Behav Med       Date:  2005       Impact factor: 3.879

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.